Altimmune Stock Discussion

9.50 is critical to hold. Under that will likely see 9.00 quickly. Here are the levels to watch.
Larger Image: tradingview.com...
$Altimmune (ALT.US)$  

$Altimmune (ALT.US)$ $10

$Altimmune (ALT.US)$ If this breaks $10 there's no stopping

$Altimmune (ALT.US)$  Exciting times ..! In a market forecasted to be 100 billion by 2030, Altimmune phase 2 results are very promising going into phase 3 trials.
Will a partner be announced or are the rumours true a buy out is eminent..!

Here are the levels to watch on this push up.
Larger Image: tradingview.com...
$Altimmune (ALT.US)$  

$Altimmune (ALT.US)$
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
Altimmune (Nasdaq: ALT) announced successful completion of End-of-Phase 2 Meeting with FDA for pemvidutide in obesity treatment. The company received agreement on Phase 3 registrational program design, which will include four Phase 3 trials (VELOCITY-1,2,3,4) enrolling approximately 5,000 subjects over 60-week periods. The trials will evaluate pemvidut...

Continuing to coil tighter. Watch for 6.55 to hold as support.
Larger Image: tradingview.com...
$Altimmune (ALT.US)$  

$Altimmune (ALT.US)$  Money tied up on some other plays, well see how long is at these levels. There are always more opportunities to come. 🐂  📈

Watching for consolidation over the 7.40 top of the POC to setup a push to 10.00+
Larger Image: tradingview.com...
$Altimmune (ALT.US)$  

$Altimmune (ALT.US)$ Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity
Benzinga· 1 min ago
In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 weeks, the lean loss ratio, defined as the change in lean mass compared to the change in total mass, was 21.9%.
Lean mass preservation was greater in subjects aged 60 years and older, in whom the ...